Statistics for The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII
Total visits
| views | |
|---|---|
| The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII | 36 |
Total visits per month
| views | |
|---|---|
| December 2024 | 0 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
| May 2025 | 0 |
| June 2025 | 0 |
File Visits
| views | |
|---|---|
| Wang-2020-The-long-term-safety-and-efficacy-o.pdf(legacy) | 73 |
| Wang-2020-The-long-term-safety-and-efficacy-o.pdf | 11 |
| 04_ArtigoRevisao_20-4_2.indd.pdf(legacy) | 1 |
Top country views
| views | |
|---|---|
| United States | 12 |
| China | 6 |
| Australia | 3 |
| Singapore | 3 |
| Mongolia | 2 |
| Portugal | 2 |
| Russia | 2 |
| Brazil | 1 |
| Germany | 1 |
| Iran | 1 |
| Latvia | 1 |
| Macau SAR China | 1 |
| Poland | 1 |